Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Orencia is now a blockbuster, selling at an annualized rate of $1.2B in 2Q12:

http://ih.advfn.com/p.php?pid=nmona&article=53586761

Sales grew 27% YoY, helped by the approval of the sub-q formulation in Jul 2011.

All told, not bad for a drug that some analysts had dismissed as an also-ran. It’s the clear leader in RA among non-TNF-a biologics, easily outselling Rituxan and Actemra.